The global hospital-acquired bacterial infections market is expected to witness a series of patent expiries between 2009 and 2016, which includes most of the top selling blockbuster drugs for urinary tract infections, pneumonia, surgical site infections and bloodstream infections. The major drugs that are set to lose patent protection include Zyvox (linezolid, 2013), Levaquin (levofloxacin, 2010), Invanz (ertapenem, 2013) and Tobi (tobramycin, 2014).
Read the news release about the hospital-associated infections market.
Read other coverage about medical supplies markets:
– Medical Device Market to Present Greater Opportunities, Greater Challenges to – Companies
– 6 Predictions on Device Market Growth in the Next Five Years
– FDA Announces 25 Actions to Improve Medical Device Approval Process
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
